FDA panel clears path for Lilly’s prasugrel-WEB ONLY
A panel of government health experts yesterday said a highly anticipated Eli Lilly and Co. blood thinner marks a significant advance over older treatments and should be approved. The nine members of the Food and Drug Administration’s cardiology advisory group unanimously voted in favor of the company’s anti-clotting drug prasugrel, saying it should be approved […]